Helping You Build Wealth With Honest Research
Since 1996. Read On...

MEMBER'S LOGIN

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Revealed
India's Third Giant Leap

This Could be One of the Biggest Opportunities for Investors




Important: We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
By submitting your email address, you also sign up for Profit Hunter, a daily newsletter from Equitymaster
covering exciting investing ideas and opportunities in India.

AD

Markets continue to slide down
Thu, 11 Aug 11:30 am

Indian stock market indices have extended their losses after opening trade on a weak note. Stocks from the realty and auto space are trading in the red, while those from the FMCG and healthcare space are trading firm.

The BSE-Sensex is down by 55 points and NSE-Nifty is down by 12 points. BSE-Midcap and BSE-Small cap indices are down by 0.4% and 0.1% respectively. The rupee is trading at 45.37 to the US dollar.

Finance stocks are trading in the red on heavy selling witnessed in India Infoline and SREI Infra. REC, the power finance company is looking at raising US$ 1 bn through FCCBs (Foreign Currency Convertible Bonds). It has approached the Power Ministry for approving the same. The state run company finances various power projects especially rural electrification initiatives. It plans to raise Rs 280-300 bn (US$ 6 bn plus) more in the current fiscal. Of these, the company will be borrowing US$ 1.5 bn from overseas. REC is looking at a mix of options for raising finance including loans from State Bank of India and issue of Swiss franc bonds.

Pharma stocks are trading marginally higher. Cadila Healthcare and Piramal Healthcare are the top gainers. Biocon Limited is the biggest loser. As per a leading financial daily, Indian pharmaceuticals company Piramal Healthcare has entered into an agreement with Indian telecom major Vodafone Essar to purchase 5.5% of issued equity share capital of Vodafone Essar Limited (VEL) from Essar. The deal is of a cash consideration worth around Rs 29 bn. The deal also has various exit options for Piramal, which includes participation in future initial public offering (IPO) of VEL and a sale of its stake to Vodafone. Earlier Vodafone had announced it would buy 33% from Essar in their joint venture VEL. But this transaction raised Vodafone's stake in the joint venture to 75.35% exceeding the foreign direct investment (FDI) limit of 74%. As a result Vodafone had to transfer at least 1.35% to an Indian investor to comply with the regulations. As far as Piramal Healthcare is concerned, the company is looking to diversify into other fields post the sale of its domestic formulations business to Abbott Laboratories for a consideration of US$ 3.72 bn.

For information on how to pick stocks that have the potential to deliver big returns, download our special report now!

View all commentaries | Archives

Read the latest Market Commentary


Equitymaster requests your view! Post a comment on "Markets continue to slide down". Click here!

  
ABOUT EQUITYMASTER

Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.

PREMIUM PRODUCTS
QUICK LINKS
POPULAR TOPICS
TRENDING TOPICS
FREE NEWSLETTERS
EQUITYMASTER SUPPORTS
  • HelpYourNGO
  • You Tube
  • Linkedin
  • Twitter
  • Telegram
  • Google Play

Copyright © Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited).

Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap

Phone +91-9136015013

Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited) (Research Analyst)
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Email: info@equitymaster.com. Website: www.equitymaster.com.
CIN:U74999MH2007PTC175407

Name of the Compliance & Grievance Officer: Ms Sonal Ramachandran
Telephone: +91-22-61434003 | Email: compliance@equitymaster.com

LEGAL DISCLAIMER:
Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited) (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.